#

Dailypharm Live Search Close
  • K-made new stroke drugs accelerate towards commercialization
  • by Son, Hyung-Min | translator Kim, Jung-Ju | Feb 19, 2024 05:45am
The efficacy of GNT Pharma¡¯s Nelonemdaz was confirmed in a later-stage clinical study
Merk and AstraZeneca were unsuccessful in their attempts. However, several Korean biopharma are challenging the field with cell therapy
New candidate products for ischemic stroke developed by Korean pharmaceutical companies are proving to be effective. As global pharmaceutical companies have faced difficulties in development, attention is drawn to the possibility of commercializing new stroke drugs made in Korea.

According to industry experts on the 17th, Phase 3 clinical demonstrated the efficacy of Nelonemdaz, a new ischemic candidate product developed by the bioventure company GNT Pharma.


Nelonemdaz is a derivative of aspirin and sulfasalazine, selectively inhibiting the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor, a receptor of glutamate. This drug can prevent neuronal injury after surgical thrombectomy by blocking NMDA-recept
  • 0
Reader Comment
0
Anonymity comment Write Operate Rule
Colse

´ñ±Û ¿î¿µ¹æ½ÄÀº

´ñ±ÛÀº ½Ç¸í°ÔÀç¿Í À͸í°ÔÀç ¹æ½ÄÀÌ ÀÖÀ¸¸ç, ½Ç¸íÀº À̸§°ú ¾ÆÀ̵𰡠³ëÃâµË´Ï´Ù. À͸íÀº ÇʸíÀ¸·Î µî·Ï °¡´ÉÇϸç, ´ë´ñ±ÛÀº À͸íÀ¸·Î µî·Ï °¡´ÉÇÕ´Ï´Ù.

´ñ±Û ³ëÃâ¹æ½ÄÀº

´ñ±Û ¸í¿¹ÀÚ¹®À§¿ø(ÆÊ-ÄڴϾð-Çʱâ¸ð¾ç ¾ÆÀÌÄÜ)À¸·Î À§ÃËµÈ µ¥Àϸ®ÆÊ ȸ¿øÀÇ ´ñ±ÛÀº ¡®°Ô½ÃÆÇÇü º¸±â¡¯¿Í ¡¯ÆîÃ帱âÇü¡¯ ¸®½ºÆ®¿¡¼­ Ç×»ó ÃÖ»ó´Ü¿¡ ³ëÃâµË´Ï´Ù. »õ·Î¿î ´ñ±ÛÀ» ¿Ã¸®´Â ÀϹÝȸ¿øÀº ¡®°Ô½ÃÆÇÇü¡¯°ú ¡®ÆîÃ帱âÇü¡¯ ¸ðµÎ ÆÊÄڴϾð ȸ¿øÀÌ ¾´ ´ñ±ÛÀÇ ÇÏ´Ü¿¡ ½Ç½Ã°£ ³ëÃâµË´Ï´Ù.

´ñ±ÛÀÇ »èÁ¦ ±âÁØÀº

´ÙÀ½ÀÇ °æ¿ì »çÀü Å뺸¾øÀÌ »èÁ¦ÇÏ°í ¾ÆÀ̵ð ÀÌ¿ëÁ¤Áö ¶Ç´Â ¿µ±¸ °¡ÀÔÁ¦ÇÑÀÌ µÉ ¼öµµ ÀÖ½À´Ï´Ù.

  • ÀúÀ۱ǡ¤ÀÎ°Ý±Ç µî ŸÀÎÀÇ ±Ç¸®¸¦ Ä§ÇØÇÏ´Â °æ¿ì

    »ó¿ë ÇÁ·Î±×·¥ÀÇ µî·Ï°ú °ÔÀç, ¹èÆ÷¸¦ ¾È³»ÇÏ´Â °Ô½Ã¹°

    ŸÀÎ ¶Ç´Â Á¦3ÀÚÀÇ ÀúÀÛ±Ç ¹× ±âŸ ±Ç¸®¸¦ Ä§ÇØÇÑ ³»¿ëÀ» ´ãÀº °Ô½Ã¹°

  • ±Ù°Å ¾ø´Â ºñ¹æ¡¤¸í¿¹¸¦ ÈѼÕÇÏ´Â °Ô½Ã¹°

    ƯÁ¤ ÀÌ¿ëÀÚ ¹× °³Àο¡ ´ëÇÑ ÀνŠ°ø°ÝÀûÀÎ ³»¿ëÀÇ ±Û ¹× Á÷Á¢ÀûÀÎ ¿å¼³ÀÌ »ç¿ëµÈ °æ¿ì

    ƯÁ¤ Áö¿ª ¹× Á¾±³°£ÀÇ °¨Á¤´ë¸³À» Á¶ÀåÇÏ´Â ³»¿ë

    »ç½Ç È®ÀÎÀÌ ¾ÈµÈ ¼Ò¹®À» À¯Æ÷ ½ÃŰ´Â °æ¿ì

    ¿å¼³°ú ºñ¾î, ¼Ó¾î¸¦ ´ãÀº ³»¿ë

    Á¤´ç¹ý ¹× °øÁ÷¼±°Å¹ý, °ü°è ¹ý·É¿¡ ÀúÃ˵Ǵ °æ¿ì(¼±°üÀ§ ¿äû ½Ã Áï½Ã »èÁ¦)

    ƯÁ¤ Áö¿ªÀ̳ª ´Üü¸¦ ºñÇÏÇÏ´Â °æ¿ì

    ƯÁ¤ÀÎÀÇ ¸í¿¹¸¦ ÈѼÕÇÏ¿© ÇØ´çÀÎÀÌ »èÁ¦¸¦ ¿äûÇÏ´Â °æ¿ì

    ƯÁ¤ÀÎÀÇ °³ÀÎÁ¤º¸(Áֹεî·Ï¹øÈ£, ÀüÈ­, »ó¼¼ÁÖ¼Ò µî)¸¦ ¹«´ÜÀ¸·Î °Ô½ÃÇÏ´Â °æ¿ì

    ŸÀÎÀÇ ID ȤÀº ´Ð³×ÀÓÀ» µµ¿ëÇÏ´Â °æ¿ì

  • °Ô½ÃÆÇ Ư¼º»ó Á¦ÇѵǴ ³»¿ë

    ¼­ºñ½º ÁÖÁ¦¿Í ¸ÂÁö ¾Ê´Â ³»¿ëÀÇ ±ÛÀ» °ÔÀçÇÑ °æ¿ì

    µ¿ÀÏ ³»¿ëÀÇ ¿¬¼Ó °ÔÀç ¹× ¿©·¯ ±â»ç¿¡ Áߺ¹ °ÔÀçÇÑ °æ¿ì

    ºÎºÐÀûÀ¸·Î º¯°æÇÏ¿© ¹Ýº¹ °ÔÀçÇÏ´Â °æ¿ìµµ Æ÷ÇÔ

    Á¦¸ñ°ú °ü·Ã ¾ø´Â ³»¿ëÀÇ °Ô½Ã¹°, Á¦¸ñ°ú º»¹®ÀÌ ¹«°üÇÑ °æ¿ì

    µ·¹ú±â ¹× Á÷¡¤°£Á¢ »ó¾÷Àû ¸ñÀûÀÇ ³»¿ëÀÌ Æ÷ÇÔµÈ °Ô½Ã¹°

    °Ô½Ã¹° Àбâ À¯µµ µîÀ» À§ÇØ ³»¿ë°ú ¹«°üÇÑ Á¦¸ñÀ» »ç¿ëÇÑ °æ¿ì

  • ¼ö»ç±â°ü µîÀÇ °ø½ÄÀûÀÎ ¿äûÀÌ ÀÖ´Â °æ¿ì

  • ±âŸ»çÇ×

    °¢ ¼­ºñ½ºÀÇ Çʿ伺¿¡ µû¶ó ¹Ì¸® °øÁöÇÑ °æ¿ì

    ±âŸ ¹ý·ü¿¡ ÀúÃ˵Ǵ Á¤º¸ °ÔÀ縦 ¸ñÀûÀ¸·Î ÇÒ °æ¿ì

    ±âŸ ¿ø¸¸ÇÑ ¿î¿µÀ» À§ÇØ ¿î¿µÀÚ°¡ ÇÊ¿äÇÏ´Ù°í ÆÇ´ÜµÇ´Â ³»¿ë

  • »ç½Ç °ü°è È®ÀÎ ÈÄ »èÁ¦

    ÀúÀÛ±ÇÀڷκÎÅÍ Çã¶ô¹ÞÁö ¾ÊÀº ³»¿ëÀ» ¹«´Ü °ÔÀç, º¹Á¦, ¹èÆ÷ÇÏ´Â °æ¿ì

    ŸÀÎÀÇ ÃÊ»ó±ÇÀ» Ä§ÇØÇϰųª °³ÀÎÁ¤º¸¸¦ À¯ÃâÇÏ´Â °æ¿ì

    ´ç»ç¿¡ Á¦°øÇÑ ÀÌ¿ëÀÚÀÇ Á¤º¸°¡ ÇãÀ§ÀÎ °æ¿ì (ŸÀÎÀÇ ID, ºñ¹Ð¹øÈ£ µµ¿ë µî)

  • ¡ØÀÌ»óÀÇ ³»¿ëÁß ÀϺΠ»çÇ׿¡ Àû¿ëµÉ °æ¿ì ÀÌ¿ë¾à°ü ¹× °ü·Ã ¹ý·ü¿¡ ÀÇÇØ Á¦À縦 ¹ÞÀ¸½Ç ¼öµµ ÀÖÀ¸¸ç, ¹Î¡¤Çü»ç»ó ó¹úÀ» ¹ÞÀ» ¼öµµ ÀÖ½À´Ï´Ù.

    ¡ØÀ§¿¡ ¸í½ÃµÇÁö ¾ÊÀº ³»¿ëÀÌ´õ¶óµµ ºÒ¹ýÀûÀÎ ³»¿ëÀ¸·Î ÆÇ´ÜµÇ°Å³ª µ¥Àϸ®ÆÊ ¼­ºñ½º¿¡ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì´Â ¼± Á¶Ä¡ ÀÌÈÄ º» °ü¸® ±âÁØÀ» ¼öÁ¤ °ø½ÃÇϰڽÀ´Ï´Ù.

    ¡Ø±âŸ ¹®ÀÇ »çÇ×Àº µ¥Àϸ®ÆÊ ¿î¿µÀÚ¿¡°Ô ¿¬¶ôÁֽʽÿÀ. ¸ÞÀÏ ÁÖ¼Ò´Â dailypharm@dailypharm.comÀÔ´Ï´Ù.

Write
Write
recently Agree DisAgree
If you want to see the full article, please JOIN US (click)